No material company-specific news briefings were available in the verified context for the period ending 2026-09-11. This report is informed by the most recent regulatory filings and institutional ownership disclosures as of the generation date [Brief - 2026-08-15].
Medtronic plc recorded trailing twelve-month revenue of $37.54 billion as of 2026-07-31, reflecting year-over-year growth of 13.73%. Net income for the same period was approximately $430 million, producing a net margin of 1.15%. Gross margin stood at 51.95% and operating margin at 18.08%. Earnings per share grew 40.74% year-over-year. The company held $1.69 billion in cash against total debt of $24.68 billion. Market capitalisation was approximately $117.3 billion, with a price-to-earnings ratio of 22.57 [SEC 10-Q - MDT - 2026-07-31].
Insider activity in the trailing 30 days comprised one transaction with a net reported value of zero, and the directional signal was recorded as mixed [SEC Form 4 - MDT - 2026-09]. On the institutional side, four notable managers opened new positions in MDT during the most recent 13F reporting period: Citadel (Ken Griffin), AQR Capital (Cliff Asness), Millennium (Izzy Englander), and Bridgewater (Ray Dalio). These disclosures represent new entries with no prior reported position on file [SEC 13F - Citadel - Q2 2026; SEC 13F - AQR Capital - Q2 2026; SEC 13F - Millennium - Q2 2026; SEC 13F - Bridgewater - Q2 2026].
The prevailing macro environment shows the 10-year US Treasury yield at 4.83% and the 2-year yield at 4.39%, producing a normal yield curve spread of 44 basis points [FRED DGS10; FRED DGS2]. This report was generated in response to a new SEC filing and material institutional position changes across multiple prominent asset managers.